FDA To Expand Role Of Scientific Advisory Board
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel will have a broader charge to look at how the agency's scientific efforts support its regulatory mission.
You may also be interested in...
Sweeping Changes At CDER Recommended In IoM Drug Safety Report
Among solutions suggested is six-year fixed term for the FDA commissioner and appointment of external advisory board to oversee cultural changes.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4